Ascendis Pharma A (ASND) EBT (2014 - 2026)

Ascendis Pharma A has reported EBT for 13 years, with the latest figure at -$56.4 million in Q1 2026.

• Quarterly EBT rose 42.69% year-over-year to -$56.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$194.2 million (up 46.61% YoY) and the FY2025 annual result came in at -$247.5 million, up 37.94% from the prior year.
• EBT fell to -$56.4 million in Q1 2026 per ASND's latest filing, from -$31.1 million in the prior quarter.
• Over five years, EBT peaked at -$31.1 million in Q4 2025 and troughed at -$206.2 million in Q4 2022.
• A 5-year average of -$106.9 million and a median of -$107.8 million in 2024 frame the typical range for EBT.
• The sharpest annual moves came in 2022 and 2025: EBT sank 85.04% in 2022, then soared 66.29% in 2025.
• Over 5 years, EBT stood at -$206.2 million in 2022, then soared by 57.68% to -$87.2 million in 2023, then surged by 54.21% to -$39.9 million in 2024, then increased by 22.19% to -$31.1 million in 2025, then plunged by 81.44% to -$56.4 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$56.4 million, -$31.1 million, and -$67.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.